| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MTNR1A |
| Uniprot No | P48039 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 296-350aa |
| 氨基酸序列 | GLLNQNFRKEYRRIIVSLCTARVFFVDSSNDVADRVKWKPSPLMTNNNVV KVDSV |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MTNR1A重组蛋白的参考文献示例(注：部分文献信息为示例性概括，非真实文献)：
1. **文献名称**: "Expression and Functional Characterization of Recombinant Human MTNR1A in Mammalian Cells"
**作者**: Emet, M., et al.
**摘要**: 研究报道了在HEK293细胞中成功表达MTNR1A重组蛋白，并验证其与褪黑激素的结合活性及下游cAMP信号抑制功能，为受体药理学研究提供工具。
2. **文献名称**: "Structural Insights into Melatonin Receptor MTNR1A by Cryo-EM"
**作者**: Stauch, B., et al.
**摘要**: 通过冷冻电镜解析MTNR1A与褪黑激素及G蛋白复合体的三维结构，揭示配体结合口袋特征及受体激活机制，助力靶向药物开发。
3. **文献名称**: "MTNR1A Polymorphisms Alter Receptor Signaling in Recombinant Cell Models"
**作者**: Jockers, R., et al.
**摘要**: 利用重组MTNR1A蛋白模型，分析基因多态性对受体表达、配体亲和力及β-arrestin招募的影响，探讨其与昼夜节律紊乱的关联。
4. **文献名称**: "Optimized Purification of Recombinant MTNR1A for High-Throughput Screening"
**作者**: Dubocovich, M.L., et al.
**摘要**: 开发基于昆虫细胞表达系统的MTNR1A重组蛋白高效纯化方案，应用于大规模化合物筛选，发现新型选择性激动剂/拮抗剂。
*提示*：实际文献需通过PubMed/Google Scholar检索确认，建议结合关键词“MTNR1A recombinant expression”、“melatonin receptor purification”、“MTNR1A structural analysis”等查找最新研究。
**Background of MTNR1A Recombinant Protein**
Melatonin receptor 1A (MTNR1A) is a G protein-coupled receptor (GPCR) that binds melatonin, a neurohormone primarily involved in regulating circadian rhythms, sleep-wake cycles, and seasonal physiological adaptations. It is one of two high-affinity melatonin receptors in humans (MTNR1A and MTNR1B) and is widely expressed in the central nervous system (e.g., suprachiasmatic nucleus), peripheral tissues (e.g., retina, immune cells, and reproductive organs), and certain cancer cells. Structurally, MTNR1A consists of seven transmembrane domains, characteristic of GPCRs, and signals primarily through Gi/o proteins, inhibiting cAMP production and modulating downstream pathways like MAPK/ERK.
Recombinant MTNR1A protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional receptor material for research. This involves cloning the MTNR1A gene into a vector, transfecting host cells, and isolating the protein via affinity chromatography, often with tags like His or FLAG for detection. Recombinant MTNR1A retains ligand-binding specificity and signaling capabilities, enabling studies on receptor-ligand interactions, structure-function relationships, and drug screening.
Research on MTNR1A recombinant protein has advanced understanding of melatonin's role in disorders like insomnia, depression, and cancer. It also aids in developing therapeutic agents targeting circadian disruptions or melatonin-related pathologies. Challenges include maintaining receptor stability during purification and ensuring proper post-translational modifications in heterologous systems. Ongoing efforts focus on crystallizing MTNR1A to resolve its 3D structure, facilitating rational drug design. Overall, MTNR1A recombinant tools remain pivotal in elucidating melatonin signaling and translational applications.
×
